Day J, Otto S, Cash K, Limaye V (2020) Clinical and histological features of immune-mediated necrotising myopathy: A multi-centre South Australian cohort study. Neuromuscul Disord 30:186–199. https://doi.org/10.1016/j.nmd.2020.02.003

Article  PubMed  Google Scholar 

Khoo T, Lilleker JB, Thong BYH et al (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19:695–712. https://doi.org/10.1038/s41584-023-01033-0

Article  PubMed  Google Scholar 

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A et al (2019) Identification of distinctive interferon gene signatures in different types of myositis. Neurology 93:E1193–E1204. https://doi.org/10.1212/WNL.0000000000008128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allenbach Y, Uzunhan Y, Toquet S et al (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 95:70–78. https://doi.org/10.1212/WNL.0000000000009727

Article  Google Scholar 

Pinal-Fernandez I, Milisenda JC, Pak K et al (2023) Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheum Dis 82:1091–1097. https://doi.org/10.1136/ard-2023-223873

Article  CAS  PubMed  Google Scholar 

Best M, Molinari N, Chasset F et al (2019) Use of anti-transcriptional intermediary factor‑1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: A systematic review and meta-analysis. Acta Derm Venereol 99:256–262. https://doi.org/10.2340/00015555-3091

Article  CAS  PubMed  Google Scholar 

Fiorentino D, Mecoli CA, Igusa T et al (2023) Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis. Arthritis Rheumatol 75:1238–1245. https://doi.org/10.1002/art.42474

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishino I, Inoue M, Tanboon J et al (2020) Association of Dermatomyositis Sine Dermatitis with Anti-Nuclear Matrix Protein 2 Autoantibodies. JAMA Neurol 77:872–877. https://doi.org/10.1001/jamaneurol.2020.0673

Article  PubMed  Google Scholar 

Oldroyd AGS, Callen JP, Chinoy H et al (2023) International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol 19:805–817. https://doi.org/10.1038/s41584-023-01045-w

Article  PubMed  Google Scholar 

Allenbach Y, Arouche-Delaperche L, Preusse C et al (2018) Necrosis in anti-SRP + and anti-HMGCR + myopathies. Neurology 90:e507–e517. https://doi.org/10.1212/WNL.0000000000004923

Article  CAS  PubMed  Google Scholar 

Mammen AL, Amato AA, Dimachkie MM et al (2023) Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol 5:e67–e76. https://doi.org/10.1016/S2665-9913(23)00003-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Preuße C, Paesler B, Nelke C et al (2022) Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol 144:353–372. https://doi.org/10.1007/s00401-022-02438-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schett G, Mackensen A, Mougiakakos D (2023) CAR T‑cell therapy in autoimmune diseases. Lancet 402:2034–2044. https://doi.org/10.1016/S0140-6736(23)01126-1

Article  CAS  PubMed  Google Scholar 

Greenberg SA, Pinkus JL, Kong SW et al (2019) Highly differentiated cytotoxic T cells in inclusion body myositis. Brain 142:2590–2604. https://doi.org/10.1093/brain/awz207

Article  PubMed  Google Scholar 

Britson KA, Ling JP, Braunstein KE et al (2022) Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med 14:1–32. https://doi.org/10.1126/scitranslmed.abi9196

Article  CAS  Google Scholar 

Lilleker JB, Naddaf E, Saris CGJ et al (2024) 272nd ENMC international workshop: 10 Years of progress—revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16–18 June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord 37:36–51. https://doi.org/10.1016/j.nmd.2024.03.001

Article  PubMed  Google Scholar 

Salem JE, Bretagne M, Abbar B et al (2023) Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov 13:1100–1115. https://doi.org/10.1158/2159-8290.CD-22-1180

Article  CAS  PubMed  Google Scholar 

Nelke C, Pawlitzki M, Kerkhoff R et al (2024) Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade. Neurol Neuroimmunol Neuroinflammation 11:1–5. https://doi.org/10.1212/NXI.0000000000200177

Article  Google Scholar 

Nelke C, Schmid S, Kleefeld F et al (2024) Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases. Acta Neuropathol 147:15. https://doi.org/10.1007/s00401-023-02669-8

Article  PubMed  PubMed Central  Google Scholar 

Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715

Article  CAS  PubMed  Google Scholar 

Holl-Ulrich K (2010) Histopathologie systemischer Vaskulitiden. Pathologe 31:67–76. https://doi.org/10.1007/s00292-009-1156-x

Article  CAS  PubMed  Google Scholar 

Rohmer J, Nguyen Y, Trefond L et al (2023) Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: Data from 196 patients. J Autoimmun. https://doi.org/10.1016/j.jaut.2023.103093

Article  PubMed  Google Scholar 

Kronbichler A, Bajema IM, Bruchfeld A et al (2024) Diagnosis and management of ANCA-associated vasculitis. Lancet 403:683–698. https://doi.org/10.1016/S0140-6736(23)01736-1

Article  CAS  PubMed  Google Scholar 

Mertz P, Wollenschlaeger C, Chasset F et al (2023) Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. Autoimmun Rev 22:103391. https://doi.org/10.1016/j.autrev.2023.103391

Article  CAS  PubMed  Google Scholar 

Krusche M, Ruffer N, Kubacki T et al (2019) Muscular polyarteritis nodosa—a case-based review. Z Rheumatol 78:173–179. https://doi.org/10.1007/s00393-019-0595-x

Article  CAS  PubMed  Google Scholar 

Ushiyama S, Shimojima Y, ichi UK et al (2020) Clinical characteristics of patients with myalgia as the initial manifestation of small and medium-sized vasculitis: a retrospective study. Rheumatol Int 40:1667–1674. https://doi.org/10.1007/s00296-020-04652-y

Article  CAS  PubMed  Google Scholar 

Andrés M, Sivera F, Alonso S, Pack C (2015) MRI myositis sine myositis: the importance of the histopathology. Rheumatol 54:76. https://doi.org/10.1093/rheumatology/keu370 (United Kingdom)

Article  Google Scholar 

Blaes F (2015) Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis 7:45–55. https://doi.org/10.1177/1759720X14566617

Article  CAS  PubMed  PubMed Central  Google Scholar 

Collins MP, Hadden RDM, Luqmani RA (2024) Vasculitic neuropathy-related disability, pain, quality of life, and autonomic symptoms: a survey of 312 patients. Baillieres Clin Rheumatol. https://doi.org/10.1093/rheumatology/keae038